Safety results of the Canadian Expanded Access Program (EAP) of palbociclib (PAL) plus letrozole (L) in postmenopausal patients (pts) with hormone receptor-positive (HR plus )/human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC) deemed appropriate candidates for first-line (1L) endocrine therapy (ET) with L.

被引：1
|
作者：
Joy, Anil A.
Verma, Shailendra
Provencher, Louise
Theall, Kathy Puyana
Lu, Dongrui
Dequen, Florence
Rayson, Daniel
机构：
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 35卷
关键词：
D O I：
10.1200/JCO.2017.35.15_suppl.e12534
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e12534
引用
收藏
页数：6
相关论文
共 50 条
  • [41] Ribociclib (RIBO) plus letrozole (LET) in male patients (pts) with hormone receptor-positive (HR plus ), human epidermal growth factor receptor-2-negative (HER2-) advanced breast cancer (ABC) and no prior endocrine therapy (ET) for ABC: Preliminary subgroup results from the phase IIIb CompLEEment-1 trial
    Zamagni, C.
    Campone, M.
    Kudryavcev, I.
    Brown-Glaberman, U.
    Cottu, P. H.
    Ring, A.
    Lu, J.
    Martin, M.
    De laurentiis, M.
    Zhou, K.
    Wu, J.
    Menon, L.
    Azim, H. A.
    ANNALS OF ONCOLOGY, 2018, 29
  • [42] Efficacy and safety of palbociclib plus endocrine therapy in Black and Hispanic patients with hormone receptor positive/human epidermal growth factor receptor 2-negative advanced breast cancer (HR+/HER2-ABC) participating in the PALOMA trials
    Isaacs, Claudine
    Mahtani, Reshma
    Lynce, Filipa
    Sleckman, Bethany
    Castrellon, Aurelio
    Kalmadi, Sujith
    Theall, Kathy Puyana
    Huang, Xin
    Bananis, Eustratios
    Rugo, Hope S.
    CANCER RESEARCH, 2022, 82 (04)
  • [43] COST-EFFECTIVENESS OF RIBOCICLIB PLUS LETROZOLE VERSUS PALBOCICLIB PLUS LETROZOLE FOR POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR POSITIVE (HR plus ), HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2-NEGATIVE (HER2-) ADVANCED/METASTATIC BREAST CANCER FROM A UK NATIONAL HEALTH SERVICE PERSPECTIVE
    Hettle, R.
    Suri, G.
    Misty, R.
    Chandiwana, D.
    Lee, A.
    VALUE IN HEALTH, 2017, 20 (09) : A433 - A433
  • [44] Ribociclib (RIB) plus fulvestrant (FUL) in hormone receptor-positive (HR plus ), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): MONALEESA-3 biomarker analyses
    Neven, P.
    Petrakova, K.
    Bianchi, G. V.
    Merino, L. De la Cruz
    Jerusalem, G.
    Beck, J. T.
    Sonke, G. S.
    Chia, S.
    Brucker, S.
    Wang, Y.
    He, W.
    Lorenc, K. Rodriguez
    Su, F.
    Im, S-A.
    ANNALS OF ONCOLOGY, 2018, 29 : 113 - +
  • [45] Efficacy and safety of palbociclib plus fulvestrant in Asian women with hormone receptor-positive (HR plus )/human epidermal growth factor-2 negative (HER2-) metastatic breast cancer (MBC) that progressed on prior endocrine therapy (ET)
    Ro, J.
    Im, S-A.
    Masuda, N.
    Im, Y-H.
    Inoue, K.
    Rai, Y.
    Nakamura, R.
    Kim, J. H.
    Zhang, K.
    Giorgetti, C.
    Schnell, P.
    Bartlett, C. Huang
    Iwata, H.
    ANNALS OF ONCOLOGY, 2015, 26 : 16 - 16
  • [46] Efficacy and safety of palbociclib plus endocrine therapy in North American women with hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer
    Gelmon, Karen A.
    Cristofanilli, Massimo
    Rugo, Hope S.
    DeMichele, Angela M.
    Joy, Anil A.
    Castrellon, Aurelio
    Sleckman, Bethany
    Mori, Ave
    Theall, Kathy Puyana
    Lu, Dongrui R.
    Huang, Xin
    Bananis, Eustratios
    Finn, Richard S.
    Slamon, Dennis J.
    BREAST JOURNAL, 2020, 26 (03): : 368 - 375
  • [47] First-line (1L) ribociclib (RIB) plus letrozole (LET) for postmenopausal women with hormone receptor-positive (HR+), HER2-advanced breast cancer (ABC): MONALEESA-2 long-term safety results.
    O'Shaughnessy, Joyce
    Campone, Mario
    Andre, Fabrice
    Nusch, Arnd
    Grischke, Eva-Maria
    Villanueva, Cristian
    Marschner, Norbert
    Winer, Eric P.
    Paluch-Shimon, Shani
    Rodriguez-Lorenc, Karen
    Hilliard, Annie
    Le Gac, Fabienne
    Ridolfi, Antonia
    Hortobagyi, Gabriel N.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [48] Longitudinal circulating tumor DNA (ctDNA) analysis in the phase 1b MONALEESASIA study of ribociclib (RIB) plus endocrine therapy (ET) in Asian patients (pts) with hormone receptor-positive (HR plus )/human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC)
    Yap, Y. S.
    Su, F.
    Joshi, M.
    Chiu, J.
    Masuda, N.
    Ito, Y.
    Ishikawa, T.
    Aruga, T.
    Kim, S. J.
    Deore, U.
    Babbar, N.
    Balbin, A.
    ANNALS OF ONCOLOGY, 2021, 32 : S459 - S460
  • [49] BUDGET IMPACT OF RIBOCICLIB PLUS LETROZOLE FOR THE TREATMENT OF POST-MENOPAUSAL WOMEN WITH HORMONE RECEPTOR-POSITIVE (HR plus ), HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2-NEGATIVE (HER2-) ADVANCED OR METASTATIC BREAST CANCER IN DENMARK
    Moller, A. H.
    Oddershede, L.
    VALUE IN HEALTH, 2019, 22 : S483 - S483
  • [50] THE ALPELISIB (ALP) EXPERIENCE IN THE SOLAR-1 AND BYLIEVE STUDIES: PERSPECTIVES FOR PRACTITIONERS CARING FOR PATIENTS (PTS) WITH HORMONE RECEPTOR-POSITIVE (HR plus ), HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2-NEGATIVE (HER2-) ADVANCED BREAST CANCER (ABC)
    Rugo, Hope S.
    Andre, Fabrice
    Park, Yeon Hee
    Drullinsky, Pamela
    Loibl, Sibylle
    Cardoso, Fatima
    Mason, Ginny
    Aubel, Dawn
    Lorenzo, Ines
    Akdere, Murat
    Ciruelos, Eva M.
    BREAST, 2021, 59 : S49 - S49
12345